Advertisement

Topics

Hart Recaps Data With Abemaciclib in HR+/HER2- Breast Cancer

06:00 EDT 11 Aug 2018 | OncLive

Abemaciclib (Verzenio) has emerged as a promising agent for patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to Lowell L. Hart, MD.

Original Article: Hart Recaps Data With Abemaciclib in HR+/HER2- Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Hart Recaps Data With Abemaciclib in HR+/HER2- Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Endocrinology
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...